See how researchers at the KTH Royal Institute of Technology and Uppsala University are using Twist’s Combinatorial Variant Libraries (CVLs) to engineer previously identified affibody molecules targeting VEGFR2 for basic biological research into the vascularization process and potentially target the treatment of several diseases including cancer and macular degeneration.  

Discover how the synthetic advantage can streamline your discovery efforts with Twist Antibody Libraries. Twist Bioscience capitalizes on its massively parallel DNA synthesis platform to generate custom antibody libraries that meet your needs. Complementing this service is the Library of Libraries, a collection of synthetic antibody libraries offered off-the-shelf by Twist Biopharma, a division of Twist Bioscience. Every ready-to-use library offers unique, drug-like antibodies and comes with advanced design support from Twist Biopharma. Compared to those from immunized sources, Twist Antibody Libraries are more diverse, cost-effective, and faster to obtain, making antibody discovery easier than ever before.

Twist's proprietary oligo synthesis technology offers a unique approach to library creation with silicon-based synthesis platform that generates high-quality oligo pools, which are used to build fully-customized, user-defined variant libraries on a single chip.